434 related articles for article (PubMed ID: 25107669)
1. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
2. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
Shao C; Yu B; Liu Y
Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
7. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
8. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
Anantharaman A; Friedlander TW
Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
[TBL] [Abstract][Full Text] [Related]
9. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
10. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
11. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
12. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
13. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
Shiota M; Yokomizo A; Naito S
J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942
[TBL] [Abstract][Full Text] [Related]
14. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
Martinez-Ariza G; Hulme C
Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
[TBL] [Abstract][Full Text] [Related]
17. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
18. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
20. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
